SCHEMBL11697241

SCHEMBL11697241

COc1ccc(C(NC(C)=O)C(=O)O)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ATM Q13315 1/20 0.56
ACACB O00763 4/20 0.55
NPSR1 Q6W5P4 1/20 0.49
CNR2 P34972 1/20 0.48
KMT2A Q03164 3/20 0.47
MEN1 O00255 2/20 0.47
LDHA P00338 1/20 0.46
CNR1 P21554 1/20 0.46
PTGS2 P35354 3/20 0.45
PTGS1 P23219 2/20 0.45
AKR1C3 P42330 2/20 0.45
AKR1C2 P52895 2/20 0.45
CDC42 P60953 1/20 0.45
RAC1 P63000 1/20 0.45
CYP1A2 P05177 1/20 0.45
TSHR P16473 1/20 0.45
SLC22A6 Q4U2R8 1/20 0.45
RAB9A P51151 1/20 0.45
TP53 P04637 1/20 0.44
ALDH1A1 P00352 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5745792 0.88 ACACB (0.56) ATMACACBNPSR1CNR2KMT2A
SCHEMBL11646318 0.85 ATM (0.55) ATMACACBNPSR1CNR2KMT2A
SCHEMBL11698235 0.85 MAPT (0.51) ATMACACBKMT2AMEN1CYP1A2
SCHEMBL7450674 0.85 MAPT (0.51) ATMACACBKMT2AMEN1CYP1A2
SCHEMBL29401218 0.85 MAPT (0.51) ATMACACBKMT2AMEN1CYP1A2
SCHEMBL30336247 0.82 ATM (0.51) ATMNPSR1CNR2KMT2AMEN1
SCHEMBL14019011 0.82 ATM (0.51) ATMNPSR1CNR2KMT2AMEN1
SCHEMBL7036247 0.82 NPSR1 (0.69) ATMACACBNPSR1CNR2KMT2A
SCHEMBL11685322 0.82 ATM (0.49) ATMACACBNPSR1CNR2KMT2A
SCHEMBL11351707 0.81 ATM (0.54) ATMNPSR1CNR2KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10590118-B2 Bicyclic heterocyclic derivatives as bromodomain inhibitors ORION CORPORATION (FI) 2020-03-17 US disclosed
US-20180339982-A1 BICYCLIC HETEROCYCLIC DERIVATIVES AS BROMODOMAIN INHIBITORS AURIGENE ONCOLOGY LIMITED (IN) 2018-11-29 US disclosed
US-10077259-B2 Bicyclic heterocyclic derivatives as bromodomain inhibitors ORION CORPORATION (FI) 2018-09-18 US disclosed
EP-3092227-B1 BICYCLIC HETEROCYCLIC DERIVATIVES AS BROMODOMAIN INHIBITORS ORION CORP (FI) 2018-07-11 EP disclosed
US-20160368906-A1 BICYCLIC HETEROCYCLIC DERIVATIVES AS BROMODOMAIN INHIBITORS ORION CORPORATION (FI) 2016-12-22 US disclosed
EP-3092227-A1 BICYCLIC HETEROCYCLIC DERIVATIVES AS BROMODOMAIN INHIBITORS ORION CORPORATION (FI) 2016-11-16 EP disclosed
WO-2015104653-A1 BICYCLIC HETEROCYCLIC DERIVATIVES AS BROMODOMAIN INHIBITORS AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) 2015-07-16 WO disclosed
US-4005088-A Process for the chemical separation of racemic modifications of α-aminocarboxylic acid derivatives, and cinchonidine salt intermediates ANDENO B.V. (NL) 1977-01-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160368906-A1 BICYCLIC HETEROCYCLIC DERIVATIVES AS BROMODOMAIN INHIBITORS BRD1, BRD2, BRD3 ATM 2383/4885ACACB 735/4885NPSR1 2263/4885
US-20180339982-A1 BICYCLIC HETEROCYCLIC DERIVATIVES AS BROMODOMAIN INHIBITORS BRD1, BRD2, BRD3 ATM 2383/4885ACACB 735/4885NPSR1 2263/4885
US-10590118-B2 Bicyclic heterocyclic derivatives as bromodomain inhibitors BRD1, BRD2, BRD3 ATM 2383/4885ACACB 735/4885NPSR1 2263/4885
US-10077259-B2 Bicyclic heterocyclic derivatives as bromodomain inhibitors BRD1, BRD2, BRD3 ATM 2383/4885ACACB 735/4885NPSR1 2263/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.